Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
Conditions: Acute Coronary Syndrome; Non ST Segment Elevation Acute Coronary Syndrome Interventions: Drug: Tafolecimab; Drug: Cholesterol Absorption Inhibitor; Drug: Statin Sponsors: China National Center for Cardiovascular Diseases; Innovent Biologics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Angioplasty | Cardiology | Cardiovascular | China Health | Cholesterol | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Research | Statin Therapy